In mild traumatic brain injury patients, Cerebrolysin increased CASI scores more than placebo between baseline and week 12.
In plain wordsIn patients with mild brain injury, Cerebrolysin improved cognitive scores more than placebo at week 12.
- Peptide
- Cerebrolysin
- Outcome
- IncreaseCASI change at week 12
- Study
n = 32
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cognition and memory · Nervous system and cognition
- Studied dose
- 30 mL once daily · intravenous infusion · 5 daysAs given in this study (human).
Measurements
- CASI change
- 21 points
- Cerebrolysin
- CASI change
- 7.6 points
- placebo
- P value
- 0.0461
- between groups
- CASI score change reported ± uncertainty term
- 20.4
- Group A (Cerebrolysin), baseline to week 12, reported as 21.0 ± 20.4; uncertainty type not stated
- CASI score change reported ± uncertainty term
- 12.1
- Group B (placebo), baseline to week 12, reported as 7.6 ± 12.1; uncertainty type not stated
Source sentences
For Group A, the CASI score difference between baseline and week 12 was 21.0 ± 20.4, a significantly greater change than that of Group B (7.6 ± 12.1) (p = 0.0461).
1 context sentence(design, population, supporting numbers)
Patients were randomized to receive Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60-min period for 5 days) or placebo (Group B, same dosage and administration of normal saline as Group A).